Hints and tips:
...Mylan, a US-based generics maker, has restarted production of hydroxychloroquine at its West Virginia plant and is looking to increase manufacturing outside of the US too....
...Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries,Inc.; and...
...The Texas judge said the intellectual property was invalid, opening the way for generic competitors Mylan and Teva to market a cheaper copycat version of the prescription eye drop Restasis....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Drugmakers already say that PBMs, insurers and wholesalers are collaborating in ways that is hurting their margins, and generic drugmakers such as Teva and Mylan have blamed more powerful customers for price...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...Among the drugmakers to have received subpoenas are industry giants Mylan and Teva Pharmaceutical. The companies’ shares are down 5.4 per cent and 8.4 per cent respectively on the report....
...However, the price of acquisition — at more than 12 times Actelion’s projected 2017 sales — was rich even by the standards of the pharmaceuticals sector, which has been engaged in furious dealmaking since...
...Teva, the world’s largest maker of copycat medicines, agreed to the $41bn acquisition of the Allergan unit last year after abandoning its hostile pursuit of Mylan....
...● Related Lex note: Asahi Group — sinking pints Mylan’s takeover of Meda turns into bad medicine for stock Mylan, the Netherlands-based drugmaker, agreed to take over Meda of Sweden for $9.9bn including...
...The saga began in April and once featured a third company, Teva Pharmaceutical, which wanted to buy Mylan (Teva ultimately struck a deal with a fourth company, Allergan, leaving Perrigo and Mylan to fight...
...Botox-maker Allergan turned to lawyers at Latham & Watkins and Wachtell, Lipton, Rosen & Katz for help as it defended itself against a $46bn hostile takeover attempt by Valeant Pharmaceuticals....
...Teva Pharmaceutical, the Israeli drugmaker, is nearing a deal to acquire Allergan’s generics drug unit for between $40bn and $45bn, said people familiar with the matter....
...As for Mylan, its shares dropped 14 per cent....
...This time it is in selling mode, divesting its generics business, which makes cheap, copycat versions of off-patent drugs, to Israel’s Teva Pharmaceutical for $40.5bn....
...On Tuesday, Israeli Teva Pharmaceutical, the largest generic drug company by revenue finally announced an unsolicited bid for rival Mylan NV, the fourth-largest global generics producer....
...Mylan shares fell 14.5 per cent to $56.37, after Teva Pharmaceuticals abandoned its attempt to take over the company and instead agreed to buy a generic drugs unit from Botox-maker Allergan in a deal valued...
...Teva Pharmaceuticals’ $40bn takeover offer for Mylan thrusts into the spotlight a company that has long been a pillar of the Israeli economy and a dominant player in the global market for low-cost generic...
...Since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions — greater than the gross domestic product of Austria....
...of other large contentious takeover battles, including Monsanto’s $45bn bid to win control of Syngenta, the Swiss agricultural chemicals group, and Teva’s $40bn offer to secure rival generic drugmaker Mylan...
...New York-listed shares of Israeli drugmaker Teva Pharmaceuticals rose more than 1 per cent to $64.16, after the company offered to buy US drugmaker Mylan....
...Mylan climbed after the Pennsylvania-based pharmaceutical company lifted its third-quarter guidance on recent product approvals and launches....
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...The other India-based generic drugmakers involved in the deal are Cadila Healthcare, Hetero Labs, Mylan Laboratories, Sequent Scientific and Strides Arcolab....
...Nine other companies doing inversions do not disclose their offshore cash while Mylan holds just $174m outside the US....
International Edition